Radar · Pulmonology in United States
Best Pulmonology Companies in United States
The 382 best Pulmonology companies in United States in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Generate Biomedicines.
By Riya SenguptaFinancials
382companies tracked
$10.8Bdisclosed funding
1unicorns
213have raised
Ranked by disclosed equity funding and recent momentum, the 382 Pulmonology companies tracked across the United States have pulled in $10.8 billion in total disclosed funding, with ReCode Therapeutics alone accounting for $342 million of that. One unicorn sits in the mix. The global pulmonology market stood at roughly $1.4 billion in 2023 and is forecast to reach $3.8 billion by 2033, a 10.3% CAGR driven by air pollution, rising rates of pulmonary disease, and persistent exposure to industrial and chemical pollutants. Nuvaira ($191M) and Nocion Therapeutics ($104M) round out the upper funding tier, with NIH, Orbimed, and HHS among the most active backers.
The revenue picture is smaller but real. Across eight validated filers, median revenue sits at $23 million, growing at 14% annually, for a combined pool of roughly $256 million. Inogen Inc posted $72 million, three times the sector median. Cornerstone Therapeutics clocked $132 million, six times over. And if you want to know where the sector's attention is pointed right now, lung cancer screening guidelines and early-stage detection are the themes pulling the most heat. Coverage overall is flat, which, I'd argue, makes the outsized earners harder to spot but more rewarding when you find them.
Ranked: Best Pulmonology companies in United States
| # | Company | Disclosed funding | Last round | Employees | Founded | Founder | Market signals (1y) | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Generate Biomedicines 🦄 Developer of a platform for generating novel protein-based therapeutic modalities 78AI top 18%Funding top 23%News top 24%Innovation top 25% All 12 signals ▾AItop 18% Fundingtop 23% Newstop 24% Innovationtop 25% Growthtop 25% Patentstop 25% Moattop 25% Talenttop 28% Markettop 45% Techbottom 43% Globalbottom 42% Fin. healthbottom 39% AI: Classified as an AI company · Holds AI/ML patents (G06N-family CPC) Funding: Raised $643M across 3 rounds · 3 rounds over 5 yrs (0.6/yr) rank vs industry peers · Fliar Intelligence Index 78/100 | $643M | 17 mo ago | 75 | 2018 | Gevorg Grigoryan Co-Founder & CTO | 6 signals IPO | 36 patents Patents concentrated in chemistry & materials | — |
| 2 | Areteia Developer of therapeutics for eosinophilic asthma | $425M | 28 mo ago | 19 | 2022 | Jorge Bartolome CEO | — | — | — |
| 3 | ReCode Therapeutics Developer of precision medicines for treating lung related diseases 67Funding top 17%Talent top 28%Moat top 31%Market top 42% All 7 signals ▾Fundingtop 17% Talenttop 28% Moattop 31% Markettop 42% Newstop 45% Techtop 48% Globalbottom 39% Funding: Raised $342M across 7 rounds · 7 rounds over 7 yrs (1.0/yr) Talent: 3 named leaders on record · 3 C-suite/founder profiles curated rank vs industry peers · Fliar Intelligence Index 67/100 | $342M | 8 mo ago | 105 | 2015 | Daniel Siegwart Co-Founder | — | — | — |
| 4 | Gossamer Bio Developer of small molecule-based therapies for treating immunological disorders, inflammation, and cancer | $330M | 34 mo ago | 102 102 → 137 (+34%) | 2017 | Faheem Hasnain Founder | 8 signals Earnings · Regulatory · Lawsuit | — | — |
| 5 | Endeavor Biomedicines Developer of therapeutics for the treatment of cancer and pulmonary diseases | $296M | 25 mo ago | 22 | 2018 | John Hood Founder and Executive Chairman | — | 29 patents Pulmonary fibrosis and lung function therapies using novel pharmaceutical compositions | — |
| 6 | Nuvaira Provider of a catheter-based system for patients suffering from COPD 57Funding top 18%Moat top 23%Product top 31%Patents top 33% All 11 signals ▾Fundingtop 18% Moattop 23% Producttop 31% Patentstop 33% Innovationtop 35% Growthtop 40% Talentbottom 49% Marketbottom 46% Techbottom 46% Globalbottom 40% Newsbottom 27% Funding: Raised $191M across 10 rounds · 10 rounds over 17 yrs (0.6/yr) Moat: Editorial + unicorn rating 8/10 · IP moat: 97 patents rank vs industry peers · Fliar Intelligence Index 57/100 | $191M | 3 mo ago | 57 | 2008 | Dennis Wahr CEO | — | 97 patents Minimally invasive therapeutic devices for respiratory, esophageal and catheter-based interventions | 1 job opening |
| 7 | Expedition Therapeutics Developer of treatments targeting inflammatory and respiratory diseases for patient care | $165M | 8 mo ago | — | 2024 | Yi Larson CEO & President | — | — | — |
| 8 | Aerin Medical Developer of therapeutic devices to improve nasal breathing | $144M | 18 mo ago | 66 66 → 156 (+136%) | 2011 | Scott Wolf Co-Founder & CMO | — | 173 patents Therapies and devices for nasal/upper airway treatment and mucus reduction | 1 award |
| 9 | Endovascular Engineering Provider of mechanical thrombectomy technologies to treat venous thromboembolism 48Funding top 18%Growth top 30%Talent top 38%News top 47% All 8 signals ▾Fundingtop 18% Growthtop 30% Talenttop 38% Newstop 47% Moatbottom 48% Globalbottom 38% Marketbottom 36% Techbottom 30% Funding: Raised $122M across 3 rounds · 3 rounds over 4 yrs (0.8/yr) Growth: Fresh capital in last 24 mo rank vs industry peers · Fliar Intelligence Index 48/100 | $122M | 2 mo ago | 19 | 2019 | Mike Rosenthal Co-Founder & Chief Operating Officer | 3 signals ▲50% Funding | — | 3 job openings · 1 internship |
| 10 | Nocion Therapeutics Developer of therapeutics for the treatment of multiple diseases 42Funding top 23%Talent top 28%Moat top 39%Global bottom 39% All 6 signals ▾Fundingtop 23% Talenttop 28% Moattop 39% Globalbottom 39% Marketbottom 34% Newsbottom 18% Funding: Raised $104M across 4 rounds · 4 rounds over 7 yrs (0.6/yr) Talent: 4 named leaders on record · 4 C-suite/founder profiles curated rank vs industry peers · Fliar Intelligence Index 42/100 | $104M | 6 mo ago | 15 15 → 19 (+27%) | 2017 | Clifford Woolf Co-Founder | — | — | — |
| 11 | Kinaset Therapeutics Developer of therapeutics to treat asthma 24Funding top 26%Talent top 28%Moat top 39%Global bottom 38% All 6 signals ▾Fundingtop 26% Talenttop 28% Moattop 39% Globalbottom 38% Marketbottom 26% Techbottom 26% Funding: Raised $68.5M across 3 rounds · 3 rounds over 6 yrs (0.5/yr) Talent: 3 named leaders on record · 3 C-suite/founder profiles curated rank vs industry peers · Fliar Intelligence Index 24/100 | $68M | 5 mo ago | 10 | 2020 | Frazer Morgan Co-Founder | — | — | — |
| 12 | Auron Therapeutics Developer of cancer therapeutics for the treatment of blood cancer | $63M | 16 mo ago | 27 | 2018 | Kate Yen Co-Founder & CEO | — | — | — |
| 13 | Xequel Bio Developer of therapeutics for multiple indications | $63M | 16 mo ago | 16 | 2005 | Jerry Peter CEO | — | — | — |
| 14 | RejuvenAir Developer of a cryosurgical device for chronic bronchitis and COPD | $60M | 21 mo ago | 35 | 2006 | — | — | — | — |
| 15 | ReAlta Life Sciences Developer of therapeutic drugs for acute inflammatory and rare diseases | $57M | 2 mo ago | 19 19 → 25 (+32%) | 2018 | Neel Krishna Co-Founder | 5 signals ▲400% Leadership | — | — |
| 16 | Belenos Biosciences Developer of bispecific antibody therapeutics for chronic inflammatory disease treatment | $48M | 23 mo ago | — | 2024 | Glenn Rosen Co-Founder & Chief Translational Officer | — | — | — |
| 17 | Aviceda Therapeutics Developer of biotherapeutics for glycol-immune diseases | $47M | 18 mo ago | 16 | 2018 | Christopher Scott Co-Founder | — | — | — |
| 18 | KORONIS BIOMEDICAL TECHNOLOGIES Developer of sensors for diagnosis of lung diseases | $40M | 9 mo ago | — | 2003 | — | — | — | — |
| 19 | Aer Therapeutics Developing an inhaled approach to treat lung disease with excess mucus and mucus plugs | $36M | 16 mo ago | 8 | 2014 | John Fahy Founder | — | — | — |
| 20 | Altesa Biosciences Developer of drugs to treat RNA viruses 27Talent top 23%Funding top 27%Moat top 48%Global bottom 45% All 6 signals ▾Talenttop 23% Fundingtop 27% Moattop 48% Globalbottom 45% Techbottom 31% Marketbottom 22% Talent: 5 named leaders on record · 5 C-suite/founder profiles curated Funding: Raised $35.0M across 2 rounds · 2 rounds over 3 yrs (0.7/yr) rank vs industry peers · Fliar Intelligence Index 27/100 | $35M | 4 mo ago | 8 | 2020 | John Clerici Co-Founder | — | — | — |
| 21 | Enalare Developer of the drug for the treatment of acute respiratory depression | $35M | 17 mo ago | 2 | 2019 | Herm Cukier CEO | — | — | — |
| 22 | Clarametyx Developer of biologic therapies and vaccines for biofilm-related chronic bacterial infections | $33M | 16 mo ago | 14 | 2019 | — | — | — | — |
| 23 | Pneuma Respiratory Developer of pulmonary drug delivery solutions | $29M | 16 mo ago | — | 2015 | Eric Hunter CEO | — | 237 patents Advanced aerosol and droplet drug delivery systems for respiratory and nasal therapeutics | — |
| 24 | Pulmotect Developer of therapeutics against lung infections | $25M | 21 mo ago | 4 | 2007 | — | — | 21 patents Immunomodulatory therapeutics targeting adaptive immunity for asthma and viral infection treatment | — |
| 25 | Telesair Provider of medical devices commercialization services | $23M | 4 mo ago | 24 | 2020 | Tyler Li Co-Founder | — | 56 patents Patents concentrated in health & consumer products | 1 award |
| 26 | Beyond Air Developer of therapeutics for multiple diseases | $22M | 20 mo ago | 98 | 2011 | Amir Avniel Co-Founder & COO | 8 signals ▼56% Earnings · Regulatory · Leadership | 75 patents Targeted gaseous nitric oxide delivery systems for oncology and therapeutic gas administration | 5 launchs |
| 27 | AeroRx Developer of nebulized combination drug therapies for respiratory diseases | $21M | 8 mo ago | — | 2023 | Mei-chang Kuo Co-Founder | — | — | — |
| 28 | Qnovia Developer of inhaled drug delivery devices to deliver a broad range of pharmaceuticals | $20M | 19 mo ago | 10 | 2018 | Mario Danek Founder & CTO | — | 46 patents Electronic vaping devices with integrated fluid delivery and pressure-sensing control | — |
| 29 | Xemed Developing inhaled diagnostic agents for respiratory diseases using hyperpolarized gas MRI | $18M | 16 mo ago | 10 | 2004 | William Hersman Founder & CEO | — | 13 patents Patents concentrated in electrical & electronics | — |
| 30 | GEn1E Developer of therapeutics for the treatment of inflammatory and rare diseases | $17M | 7 mo ago | 19 | 2018 | Ritu Lal Co-Founder & CEO | — | — | — |
| 31 | Rejuvenation Technologies Developer of nucleoside-modified TERT mRNA for antiaging | $15M | 13 mo ago | 12 | 2012 | Glenn Markov Co-Founder | — | — | — |
| 32 | Miist Therapeutics Developer of inhaled therapies for rapid symptom relief | $13M | 16 mo ago | — | 2022 | Dalton Signor Founder & CEO | — | — | — |
| 33 | Securisyn Developer of airway management system for ventilated patients | $11M | 10 mo ago | 10 | 2011 | Arthur Kanowitz Co-Founder & CEO | — | — | — |
| 34 | Climatic Developer of a respiratory device designed to improve lung health 35Talent top 38%Funding top 39%Tech bottom 37%Global bottom 33% All 4 signals ▾Talenttop 38% Fundingtop 39% Techbottom 37% Globalbottom 33% Talent: 2 named leaders on record · 2 C-suite/founder profiles curated Funding: Raised $10.0M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) rank vs industry peers · Fliar Intelligence Index 35/100 | $10M | 4 mo ago | — | 2023 | Margaret Wishingrad Co-Founder | — | — | 2 launchs · 1 award |
| 35 | ABM Respiratory Care Developer of devices for ventilation and airway clearance 45Growth top 35%Moat top 38%Funding top 40%Product top 40% All 9 signals ▾Growthtop 35% Moattop 38% Fundingtop 40% Producttop 40% Techtop 47% Talentbottom 49% Marketbottom 39% Globalbottom 37% Newsbottom 18% Growth: Fresh capital in last 24 mo Moat: Editorial + unicorn rating 5/10 · 1 curated direct competitors tracked rank vs industry peers · Fliar Intelligence Index 45/100 | $10M | 11 mo ago | 54 | 2017 | Vinay Joshi CTO and Founder | — | — | — |
| 36 | LibAirty Provider of airway clearance system synchronizing controlled breathing with chest compressions 24Funding top 50%Talent bottom 49%Global bottom 36% All 3 signals ▾Fundingtop 50% Talentbottom 49% Globalbottom 36% Funding: Raised $9.3M across 2 rounds · 2 rounds over 1 yrs (2.0/yr) Talent: 1 named leader on record · 1 C-suite/founder profile curated rank vs industry peers · Fliar Intelligence Index 24/100 | $9M | 3 mo ago | — | 2016 | Anat Shani CEO | — | — | — |
| 37 | Vascular BioSciences Vascular BioSciences: Pioneering targeted therapies, interventional devices, and molecular diagnostics | $8M | 14 mo ago | 24 | 1990 | David Mann CEO & Chairman | — | — | — |
| 38 | safeBVM Provider of an ventilation technique for emergency conditions | $8M | 16 mo ago | 6 | 2017 | Haris Shekhani Co-Founder & CEO | — | 18 patents Patents concentrated in health & consumer products | — |
| 39 | Liberate Medical Developing respiratory muscle stimulator technology to liberate patients from mechanical ventilation 9Funding top 38%Moat top 48%Global bottom 32%Market bottom 27% All 5 signals ▾Fundingtop 38% Moattop 48% Globalbottom 32% Marketbottom 27% Techbottom 24% Funding: Raised $6.8M across 6 rounds · 6 rounds over 10 yrs (0.6/yr) Moat: Editorial + unicorn rating 5/10 · 9 curated direct competitors tracked rank vs industry peers · Fliar Intelligence Index 9/100 | $7M | 10 mo ago | 10 | 2013 | — | — | — | — |
| 40 | LEADOPTIK Provider of AI-powered optical processors | $7M | 9 mo ago | 8 | 2020 | Jiang You Co-Founder & VP of Medical Imaging | — | 13 patents Miniaturized optical catheters and diffractive lenses for advanced endoscopic imaging and biopsy | — |
| 41 | Belluscura Provider of medical devices for laparoscopic procedures | $6M | 16 mo ago | 21 | 2015 | — | — | 31 patents Respiratory support and oxygen therapy devices, including concentrators, ventilators, and ECMO systems. | — |
| 42 | ReNeuroGen Developer of therapeutics to treat neutrophil-mediated diseases | $6M | 14 mo ago | 4 | 2016 | Kirkwood Pritchard Co-Founder | — | 3 patents Chemico‑pharmacology platforms for drug discovery and therapeutic method development | — |
| 43 | Rare Air Health Provider of precision pulmonary drug delivery platform | $5M | 5 mo ago | — | 2021 | Kirk Gerner CEO | Founder | — | — | — |
| 44 | Flyp Nebulizer Developer of a portable nebulizer for asthma and COPD | $4M | 4 mo ago | 24 | 2017 | — | — | — | — |
| 45 | Pearl Diagnostics Foundation focused on detection and prevention of fungal infections 13Funding top 35%Talent bottom 49%Global bottom 32%Market bottom 20% All 4 signals ▾Fundingtop 35% Talentbottom 49% Globalbottom 32% Marketbottom 20% Funding: Raised $3.5M across 5 rounds · 5 rounds over 4 yrs (1.2/yr) Talent: 1 named leader on record · 1 C-suite/founder profile curated rank vs industry peers · Fliar Intelligence Index 13/100 | $4M | 3 mo ago | 6 | 2014 | Kieren Marr Founder & CEO | — | — | — |
| 46 | Aqualung Therapeutics Biotech developing novel anti-inflammatory therapies for immune-driven diseases | $3M | 6 mo ago | 5 | 2010 | Joe Gn Garcia Md Founder and CEO | — | — | — |
| 47 | ReddyPort Innovative oral care and communication solutions for non-invasive ventilation (NIV) patients | $3M | 8 mo ago | 6 | 2015 | Tony Lair CEO | — | 10 patents Advanced positive‑pressure ventilation devices and integrated monitoring accessories for respiratory care | — |
| 48 | Inhalon Biopharma Developing inhaled antibody treatments for acute respiratory infections, a clinical-stage biotechnology… | $2M | 9 mo ago | 8 | 2018 | — | — | — | — |
| 49 | Allinaire Therapeutics Developing novel therapeutics for cardiopulmonary diseases, including PAH and COPD | $2M | 4 mo ago | 4 | 2016 | — | — | — | — |
| 50 | Longeveron Developer of cellular therapies for aging-related and life-threatening conditions | $1M | 3 mo ago | 23 23 → 41 (+78%) | 2014 | Joshua Hare Co-Founder | 4 signals ▼20% Leadership · Earnings | 38 patents Mesenchymal stem cell therapeutics and potency assays for neurodegenerative and sexual health | 1 job opening |
Top 12 Pulmonology companies in United States
#1
Series E · Minneapolis, Minnesota · founded 2008 · 57 employees$191.1Mraised▾
Series E · Minneapolis, Minnesota · founded 2008 · 57 employees
Provider of a catheter-based system for patients suffering from COPD. The company is developing Nuvaira Lung Denervation System, a catheter-based system used to treat the overactive airway nerves in a procedure called Targeted Lung Denervation (TLD). It provides an ablative therapy that opens obstructed airways to improve breathing.
Fliar Intelligence Index™ 57how this company ranks against its industry peers
Funding
top 18%Moat
top 23%Product
top 31%Patents
top 33%Innovation
top 35%Growth
top 40%Funding: Raised $191M across 10 rounds · 10 rounds over 17 yrs (0.6/yr) · Last round Series E (Feb 2026)
Moat: Editorial + unicorn rating 8/10 · IP moat: 97 patents · Soonicorn
Product: 2 distinct product lines · Company stage: Series E
Audience (LinkedIn): 6k LinkedIn followers — 3.7% of this cohort's audience
Hiring (LinkedIn): 3 hiring posts in 12 mo (public) · momentum -1 · hiring: Director/Sr. Director of Clinical, Director / Senior Director of Clinical
Funding rounds
- Feb 2026Series E$35.8M
- Nov 2023Series E$15.1M
- Jan 2022Series E$31.3M
- Feb 2019Series E$79M
Founders & team
Investors
Advanced Technology Ventures, Morgenthaler, Split Rock Partners, Versant Ventures, USVP, Endeavour Vision
Tech stack
Apple Icloud MailCloudflareCloudflare Bot ManagementDocusignGodaddyGoogle Analytics
#2
Series C · Menlo Park, California · founded 2019 · 19 employees$122.3Mraised▾
Series C · Menlo Park, California · founded 2019 · 19 employees
Provider of mechanical thrombectomy technologies to treat venous thromboembolism. It offers Hēlo Thrombectomy System designed to remove clots efficiently using a dual-action mechanism. It combines aspiration and mechanical clot disruption with a small profile catheter that expands for high-performance clot engagement.
Fliar Intelligence Index™ 48how this company ranks against its industry peers
Funding
top 18%Growth
top 30%Talent
top 38%News
top 47%Moat
bottom 48%Global
bottom 38%Funding: Raised $122M across 3 rounds · 3 rounds over 4 yrs (0.8/yr) · Last round Series C (Apr 2026)
Growth: Fresh capital in last 24 mo
Talent: 2 named leaders on record · 2 C-suite/founder profiles curated
Audience (LinkedIn): 4k LinkedIn followers — 2.6% of this cohort's audience
Hiring (LinkedIn): 3 hiring posts in 12 mo (public) · momentum +3 · hiring: Area Sales Manager, Director of Finance & Accounting
Funding rounds
- Apr 2026Series C$80M
- Feb 2025Series B$42M
- Apr 2022Seed—
- Sep 2021Grant (prize money)$298.2K
Founders & team
Investors
Cordis, Sante, 415 CAPITAL, Panakes Partners, S3 Ventures, M&L Healthcare
Tech stack
Apache Http ServerApple Icloud MailBluehostBootstrapGoogle AnalyticsGsap
#3
Series C · Norfolk, Virginia · founded 2018 · 19 employees$56.5Mraised▾
Series C · Norfolk, Virginia · founded 2018 · 19 employees
Developer of therapeutic drugs for acute inflammatory and rare diseases. The company's EPICC peptides are based on research into the human astrovirus, HAstV-1, which causes a non-inflammatory, self-limiting gastroenteritis unique among viruses by inhibiting components of the innate immune system. The company’s pipeline is led by RLS-0071, for the treatment of acute exacerbations of chronic obstructive pulmonary disease and acute graft-versus-host disease.
LinkedIn Pulse recent public activity · Jul 2026
Audience: 4k LinkedIn followers — 2.5% of this cohort's audience
Funding rounds
- Apr 2026Series C$40M
- Dec 2024Series B$25M
- Feb 2023Series B$29.9M
- Apr 2021Series A$20M
Founders & team
Investors
Marathon Pharma
#4
Series B · Menlo Park, California · founded 2015 · 105 employees$342Mraised▾
Series B · Menlo Park, California · founded 2015 · 105 employees
Developer of precision medicines for treating lung-related diseases. The pipeline includes lead programs which includes RCT1100 an inhaled mRNA-based investigational therapy for primary ciliary dyskinesia caused by mutations in the DNAI1 gene and RCT2100 is an inhaled mRNA-based investigational therapy for cystic fibrosis. It has proprietary non-viral lipid nanoparticle platform that enables the delivery of a variety of payloads, and organ targeting of nucleic acid and protein payloads via both systemic and local delivery.
Fliar Intelligence Index™ 67how this company ranks against its industry peers
Funding
top 17%Talent
top 28%Moat
top 31%Market
top 42%News
top 45%Tech
top 48%Funding: Raised $342M across 7 rounds · 7 rounds over 7 yrs (1.0/yr) · Last round Series B (Sep 2025)
Talent: 3 named leaders on record · 3 C-suite/founder profiles curated
Moat: Editorial + unicorn rating 8/10 · Soonicorn · 9 curated direct competitors tracked
Funding rounds
- Sep 2025Series B$29M
- Sep 2023Series B$50M
- Jan 2023Series B$10M
- Jun 2022Series B$120M
Founders & team
Investors
Orbimed, Colt Ventures, Vida Ventures, Cystic Fibrosis Foundation, Solasta Ventures, Bioluminescence Ventures
#5
Series B · Waltham, Massachusetts · founded 2017 · 15 employees$104Mraised▾
Series B · Waltham, Massachusetts · founded 2017 · 15 employees
Developer of therapeutics for the treatment of multiple diseases. The company develops small-molecule therapies that selectively target and silence actively firing nociceptors to treat conditions like chronic cough, itch, pain, and inflammation.
Fliar Intelligence Index™ 42how this company ranks against its industry peers
Funding
top 23%Talent
top 28%Moat
top 39%Global
bottom 39%Market
bottom 34%News
bottom 18%Funding: Raised $104M across 4 rounds · 4 rounds over 7 yrs (0.6/yr) · Last round Series B (Dec 2025)
Talent: 4 named leaders on record · 4 C-suite/founder profiles curated
Moat: Editorial + unicorn rating 7/10 · 10 curated direct competitors tracked
Audience (LinkedIn): 3k LinkedIn followers
Funding rounds
- Dec 2025Series B$23M
- Feb 2024Series B$62M
- Jan 2021Series A$15M
- Apr 2019Series A$27M
Founders & team
Investors
Arkin Holdings, Monograph, Canaan, F-Prime Capital, Mass General Brigham, Mission BioCapital
#6
Series B · Boston, Massachusetts · founded 2020 · 10 employees$68.5Mraised▾
Series B · Boston, Massachusetts · founded 2020 · 10 employees
Developer of therapeutics to treat asthma. The company's proprietary product includes KN-002 which is an inhibitor of pan-JAK used to treat severe asthma. It is inhaled and delivered to the site of inflammation in the lung and minimizes systemic exposure.
Fliar Intelligence Index™ 24how this company ranks against its industry peers
Funding
top 26%Talent
top 28%Moat
top 39%Global
bottom 38%Market
bottom 26%Tech
bottom 26%Funding: Raised $68.5M across 3 rounds · 3 rounds over 6 yrs (0.5/yr) · Last round Series B (Jan 2026)
Talent: 3 named leaders on record · 3 C-suite/founder profiles curated
Moat: Editorial + unicorn rating 7/10 · 9 curated direct competitors tracked
Audience (LinkedIn): 2k LinkedIn followers
Funding rounds
- Jan 2026Series B$103M
- Jul 2023Series A$28.5M
- Nov 2020Series A$40M
Founders & team
Investors
5AM Ventures, Atlas Venture, Gimv, EQT, RA Capital Management, Forge Life Science Partners
#7
Series A · San Diego, California · founded 2024$165Mraised▾
Series A · San Diego, California · founded 2024
Developer of treatments targeting inflammatory and respiratory diseases for patient care. The company focuses on treatments addressing fundamental disease mechanisms for chronic obstructive pulmonary disease. Their therapy targets neutrophilic inflammation, a pathway driving tissue damage and lung function decline. The lead candidate is an oral DPP1 inhibitor being developed for COPD. It aims to deliver improvement for patients lacking disease-controlling options.
LinkedIn Pulse recent public activity · Jul 2026
Audience: 3k LinkedIn followers
Funding rounds
- Oct 2025Series A$165M
Founders & team
Investors
Sofinnova Investments, Novo Holdings, Forbion, Dawn Biopharma, Adage Capital Management, Balyasny Asset Management
#8
Series B · College Park, Georgia · founded 2020 · 8 employees$35Mraised▾
Series B · College Park, Georgia · founded 2020 · 8 employees
Developer of drugs to treat RNA viruses. The lead product of the company ALT-2023 is a broadly active nucleoside analog to address most Enteroviruses & Flaviviruses. Other drug candidate includes Vapendavir a capsid inhibitor with potent activity across Rhinovirus, Influenza, and Respiratory Syncytial Virus (RSV).
Fliar Intelligence Index™ 27how this company ranks against its industry peers
Talent
top 23%Funding
top 27%Moat
top 48%Global
bottom 45%Tech
bottom 31%Market
bottom 22%Talent: 5 named leaders on record · 5 C-suite/founder profiles curated
Funding: Raised $35.0M across 2 rounds · 2 rounds over 3 yrs (0.7/yr) · Last round Series B (Feb 2026)
Moat: Editorial + unicorn rating 4/10 · 10 curated direct competitors tracked
Audience (LinkedIn): 2k LinkedIn followers
Funding rounds
- Feb 2026Series B$75M
- Dec 2022Series B$35M
Founders & team
Investors
Forbion, Sanofi, Medicxi, Pitango, Atlantic Partners, GRA Venture Fund
#9
Series A · Orange, California · founded 2020 · 24 employees$22.8Mraised▾
Series A · Orange, California · founded 2020 · 24 employees
Provider of medical devices commercialization services
LinkedIn Pulse recent public activity · Jul 2026
Audience: 2k LinkedIn followers
Activity: 1 awards announced in 12 mo
Funding rounds
- Feb 2026Series A$3M
- Jan 2023Series A$22.8M
Founders & team
Investors
Pasaca Capital, Zhen Cheng Capital, ShangBay Capital, Device of Tomorrow Capital, Berkeley Catalyst Fund, Honeywell Ventures
#10
Public · Somerville, Massachusetts · founded 2018 · 75 employees$643Mraised▾
Public · Somerville, Massachusetts · founded 2018 · 75 employees
Developer of a platform for generating novel protein-based therapeutic modalities. The platform aims to expand technical possibilities to change how medicines are made. It studies proteins to learn rules by which nature encodes function. The company generates medicines across therapeutic modalities with speed and success.
Fliar Intelligence Index™ 78how this company ranks against its industry peers
AI
top 18%Funding
top 23%News
top 24%Innovation
top 25%Growth
top 25%Patents
top 25%AI: Classified as an AI company · Holds AI/ML patents (G06N-family CPC)
Funding: Raised $643M across 3 rounds · 3 rounds over 5 yrs (0.6/yr) · Last round Series C (Dec 2024)
News: 6 BI events in 12 mo (of 13 tracked, 3 types) · 6 high-value events (IPO/M&A/funding/contracts) in 12 mo · Top themes: IPO
Audience (LinkedIn): 58k LinkedIn followers — 37.3% of this cohort's audience
Funding rounds
- Dec 2024Series C—
- Sep 2023Series C$273M
- Nov 2021Series B$370M
- Sep 2020Series A$50M
Founders & team
Investors
Amgen, Mirae Asset Capital, Pictet Group, ADIA, Fidelity Investments, T. Rowe Price
Tech stack
Amazon Web ServicesApple Icloud MailCookiebotCraft CmsGoogle AnalyticsGsap
#11
Funding Raised · Minneapolis, Minnesota · founded 2003$40.2Mraised▾
Funding Raised · Minneapolis, Minnesota · founded 2003
Developer of sensors for diagnosis of lung diseases
Funding rounds
- Aug 2025Grant (prize money)$389K
- Aug 2025Grant (prize money)$1.9M
- 2024Grant (prize money)$1M
- 2021Grant (prize money)$3.4M
Investors
HHS, ED
Tech stack
Squarespace CommerceSquarespaceHstsOpen Graph
#12
Series A · Jersey City, New Jersey · founded 2016$9.3Mraised▾
Series A · Jersey City, New Jersey · founded 2016
Provider of airway clearance system synchronizing controlled breathing with chest compressions. The system facilitates controlled breathing at different lung volumes. Airflow is directed to clear small airways. The system is designed to keep lungs clear of mucus build-up and infections. It aims to reduce symptoms with daily sessions. The device is intended to improve respiratory health and quality of life.
Fliar Intelligence Index™ 24how this company ranks against its industry peers
Funding
top 50%Talent
bottom 49%Global
bottom 36%Funding: Raised $9.3M across 2 rounds · 2 rounds over 1 yrs (2.0/yr) · Last round Series A (Feb 2026)
Talent: 1 named leader on record · 1 C-suite/founder profile curated
Global: Single-market focus (United States)
Funding rounds
- Feb 2026Series A$5M
- Aug 2025Series A$4.3M
Founders & team
Investors
Njeda, Edge Medical Ventures, New Jersey Innovation Evergreen Fund
Funding & investor landscape
$10.8Btotal disclosed funding
221companies funded
872disclosed rounds
2rounds last 90 days
Most active investors
New Enterprise Associates7 rounds
Notable founders
Dennis Wahr
CEO · Nuvaira
Mike Rosenthal
Co-Founder & Chief Operating Officer · Endovascular Engineering
Dan Rose
CEO · Endovascular Engineering
Neel Krishna
Co-Founder · ReAlta Life Sciences
Kenji Cunnion
Co-Founder · ReAlta Life Sciences
Daniel Siegwart
Co-Founder · ReCode Therapeutics
Philip Thomas
Co-Founder · ReCode Therapeutics
Clifford Woolf
Co-Founder · Nocion Therapeutics
Bruce Bean
Co-Founder · Nocion Therapeutics
Frazer Morgan
Co-Founder · Kinaset Therapeutics
Roger Heerman
Co-Founder · Kinaset Therapeutics
Yi Larson
CEO & President · Expedition Therapeutics
Prism market signals · United States · country-scoped Prism corpus, 11,104,248 docs
Market landscape — 10 sub-themes by coverage
Share of Pulmonology coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
Common questions
How many Pulmonology companies are there in United States?
Radar tracks 382 indexable Pulmonology companies headquartered in United States that meet our profile-completeness bar.
What is the total funding raised by Pulmonology companies in United States?
The Pulmonology companies in United States on this list have raised a combined $10.8B in disclosed equity funding across 221 funded companies.
Which is the highest-funded Pulmonology company in United States?
Generate Biomedicines is the highest-funded Pulmonology company in United States, with $643M in disclosed equity funding.
How many Pulmonology companies in United States are funded?
221 of the 382 Pulmonology companies in United States on this list have disclosed at least one equity funding round.
How many Pulmonology unicorns are there in United States?
1 Pulmonology company in United States on this list is valued at $1B or more.
Who are the top investors in United States Pulmonology companies?
The most active investors in United States Pulmonology companies on this list include HHS, National Science Foundation, NIH, Canaan, Orbimed.
Riya SenguptaFinancials
Riya reads income statements for fun. She covers the real money in a sector — revenue, growth, who actually earns — and never met a vague claim she didn't want a number for.